Anti-Bribery and Anti-Corruption • Third-Party Due Diligence • Regional Transparency Initiatives • Incorporating a Culture of Ethics
Pharmaceutical, biotech and medical device companies in Latin America are stepping up to combat bribery and corruption challenges. In an era of emerging compliance risks and political unrest, it is critical that life sciences organizations develop robust and tailored third-party and distributor management programs along with continuous risk-based audition and monitoring of third-parties. Join us this May at CBI’s PCC Latin America to strengthen compliance programs, increase transparency and commit to a culture of ethics.
Program Highlights Include:
- Break down recent investigations and determine impact
on regional enforcement trends - Analyze how Sunshine Act and other U.S. regulations
influence health law in Latin America - Examine strategies to communicate the importance of
adhering to international compliance laws - Gain insight on advancements in data analytics and
applications within Latin American compliance programs
to improve efficiency and efficacy - Mitigate cross-border risks and maximize HCP relationships
- Overcome FMV and transparency reporting challenges in
HCP interactions
Comments